BioCentury
ARTICLE | Clinical News

DPX-Survivac: Additional Phase I/II data

October 15, 2012 7:00 AM UTC

Interim data from 9 patients in the Phase I portion of a North American Phase I/II trial showed that 0.5 mL subcutaneous DPX-Survivac in combination with low-dose oral cyclophosphamide every 3 weeks for 6 weeks produced targeted immune responses after only 1 vaccination and generally showed higher antigen-specific immunity compared to 0.1 mL DPX-Survivac plus cyclophosphamide. Additionally, high-dose DPX-Survivac plus cyclophosphamide produced an average stimulation factor of 350 times over baseline responses following the second vaccination. One patient had an average stimulation factor of 850 times over baseline responses. Immunovaccine said stimulation factor is the number of interferon (IFN)-positive cells following a short pulse with peptides contained in the vaccine as measured by an enzyme-linked immunospot (ELISPOT) assay. ...